BeOne Medicines (ONC) stock is in focus after the company reported significantly improved second quarter 2026 earnings and raised its full year revenue and GAAP operating income guidance earlier this month.

Following the earnings beat and raised 2026 guidance, BeOne Medicines stock has picked up momentum, with an 18.31% 1 month share price return and a 19.57% 3 month share price return. That sits alongside an 18.12% 1 year total shareholder return and a very large 3 year total shareholder return that hints at how investors have been reassessing both growth prospects and risk over time.

If BeOne Medicines' recent move has you looking at other oncology and biotech opportunities linked to artificial intelligence and data driven drug development, now can be a useful moment to scan 42 healthcare AI stocks

After a sharp move on the back of BeOne Medicines' upgraded 2026 outlook, the next consideration is timing. Does it make more sense to accept today’s price, or wait in the hope of a more comfortable entry after the excitement cools?

Most Popular Narrative: 10.5% Undervalued

The most followed narrative currently places BeOne Medicines' fair value at $412.35 per share, compared with the last close at $369.15. That gap reflects a detailed view on how its oncology portfolio and pipeline could translate into future cash flows using a 7.1% discount rate.

The company's robust pipeline, including multiple late-stage oncology assets (over 20 Phase III trials and >10 proof-of-concept readouts expected in the next 18 months), leverages internal R&D capabilities and the GlueXplorer™ platform to rapidly develop targeted, personalized medicines. This approach is well-aligned with the shift toward precision therapeutics and is presented as supporting long-term earnings and margin expansion as products commercialize.

Curious what sits behind that premium fair value for BeOne Medicines. The narrative leans on ambitious revenue growth, rising profit margins and a higher future earnings multiple. Want to see which specific forecasts and time frames drive that conclusion.

Result: Fair Value of $412.35 (UNDERVALUED)

However, BeOne Medicines still faces concentration risk around BRUKINSA and exposure to tighter U.S. drug pricing, which could pressure margins and challenge the current fair value story.

Another View: What BeOne Medicines’ P/E Is Telling You

The earlier fair value estimate points to BeOne Medicines trading at a discount to projected cash flows. The P/E picture looks different. ONC trades on about 64x earnings, compared with roughly 27.4x for peers and a fair ratio of 34.7x. That is a large premium. Is that extra valuation cushion or valuation risk in your view?

Next Steps

If the mix of enthusiasm and caution around BeOne Medicines feels familiar, that is the point. Act while the data is fresh and weigh the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond BeOne Medicines?

If you stop with BeOne Medicines, you might miss other stocks that better fit your goals. Put the Simply Wall St Screener to work while this research is fresh.

• Target reliable income by scanning for companies built around strong payouts using the 11 dividend fortresses
• Hunt for quality at a reasonable price with the screener containing 20 high quality undiscovered gems
• Prioritise resilience and sleep-at-night holdings through the 79 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.